CIK 0000872589 · Large accelerated filer
REGENERON PHARMACEUTICALS, INC.
Sign in to watch- Ticker
- REGN
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- NY
- Entity type
- operating
- EIN
- 133444607
- Phone
- 9148477000
- Business address
- 777 OLD SAW MILL RIVER ROAD, TARRYTOWN, NY, 10591
- Former names
- REGENERON PHARMACEUTICALS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $51,901,544
- in 11 filings, $8.6M under 10b5-1 plans
Net −$51,901,544. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-11-02 | SING GEORGE L Director | Option exercise · Non-Qualified Stock Option (right to buy) | −7,439 | 0 | ||
| 2026-11-02 | POON CHRISTINE A Director | Option exercise | +7,830 | $376.69 | $2.9M | 13,049 |
| 2026-11-02 | POON CHRISTINE A Director | Sale | −218 | $966.74 | $211K | 12,831 |
| 2026-11-02 | POON CHRISTINE A Director | Sale | −772 | $967.38 | $747K | 12,059 |
| 2026-11-02 | POON CHRISTINE A Director | Sale | −2,499 | $968.58 | $2.4M | 9,560 |
| 2026-11-02 | POON CHRISTINE A Director | Sale | −3,203 | $969.50 | $3.1M | 6,357 |
| 2026-11-02 | POON CHRISTINE A Director | Sale | −937 | $970.51 | $909K | 5,420 |
| 2026-11-02 | POON CHRISTINE A Director | Sale | −201 | $971.31 | $195K | 5,219 |
| 2026-11-02 | POON CHRISTINE A Director | Option exercise · Non-Qualified Stock Option (right to buy) | −7,830 | 0 | ||
| 2026-10-30 | Guarini Kathryn Director | Option exercise 10b5-1 | +400 | $719.37 | $288K | 1,003 |
| 2026-10-30 | Guarini Kathryn Director | Sale 10b5-1 | −400 | $900.00 | $360K | 603 |
| 2026-10-30 | Guarini Kathryn Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −400 | 758 | ||
| 2026-10-30 | McCourt Marion EVP Commercial | Sale 10b5-1 | −1,132 | $869.43 | $984K | 10,871 |
| 2026-10-30 | BROWN MICHAEL S Director | Option exercise 10b5-1 | +1,929 | $725.89 | $1.4M | 3,309 |
| 2026-10-30 | BROWN MICHAEL S Director | Sale 10b5-1 | −1,929 | $875.00 | $1.7M | 1,380 |
| 2026-10-30 | BROWN MICHAEL S Director | Option exercise · Non-Qualified Stock Option (right to buy) 10b5-1 | −1,929 | 0 | ||
| 2026-10-14 | MURPHY ANDREW J Co-Chief Scientific Officer | Sale 10b5-1 | −6 | $753.76 | $5K | 51,974 |
| 2026-10-14 | MURPHY ANDREW J Co-Chief Scientific Officer | Sale 10b5-1 | −35 | $755.91 | $26K | 51,939 |
| 2026-10-14 | MURPHY ANDREW J Co-Chief Scientific Officer | Sale 10b5-1 | −16 | $757.68 | $12K | 51,923 |
| 2026-10-14 | MURPHY ANDREW J Co-Chief Scientific Officer | Sale 10b5-1 | −24 | $758.16 | $18K | 51,899 |
Page 3 of 49 · 971 trades